IntelliPlex® BRAF V600 Mutation Kit
User Manual

REF **82004** **24 Reactions**

CE IVD **For In-Vitro Diagnostic Use**

PlexBio Co., Ltd.
6F-1, No. 351, Yangguang St., Neihu Dist., Taipei City, 11491, Taiwan
TEL: + 886-2-2627-5878
http://www.plexbio.com

European Authorized Representative:
Medical Device Saftey Services GmbH (MDSS)
Schiffgraben 41, 30175, Hannover, Germany

IMPORTANT:
Read the instructions carefully prior to use

1. INTENDED USE

The IntelliPlex BRAF V600 Mutation Kit, based on πCode® technology and PlexBio's instrument platform, is an in-vitro molecular assay intended for qualitative identification of 7 nucleotide changes in exon 15 of the *BRAF* gene using DNA samples derived from formalin-fixed paraffin-embedded (FFPE) human tissue, such as melanoma, non-small cell lung cancer (NSCLC) or metastatic colorectal cancer (mCRC). The IntelliPlex BRAF V600 Mutation Kit is for in vitro diagnostic use and intended to be used by trained laboratory professionals.

2. INTRODUCTION

The mitogen-activated protein kinase (MAPK) pathway is an important signaling pathway in a number of cancers. Activating mutations in BRAF result in constitutive activation of the RAF-MEK-ERK signaling cascade, leading to unchecked cell proliferation and growth. Many types of cancers, including melanoma, NSCLC, and mCRC, are associated with activating mutations in the BRAF gene, often found in exon 15 on codon 600. Patients carrying BRAF V600 mutations may be particularly responsive to BRAF inhibitors and MEK inhibitors. Assessment of BRAF mutations is therefore crucial for the treatment evaluation of patients with certain cancers. SelectAmp and πCode technology enables the multiplex, single-well detection of single nucleotide mutations in the *BRAF* gene from specimens containing large amounts of wild-type genomic DNA with significantly reduced sample requirement compared to conventional methods. The **IntelliPlex BRAF V600 Mutation Kit** identifies 7 nucleotide changes on exon 15 of the BRAF gene (Table 1).

Table 1. Mutations Detected

Gene	Exon Codon	Amino Acid Change	Nucleotide Change	Cosmic ID
BRAF	Exon 15 Codon600	p. V600E1	c.1799T>A	476
		p.V600E2	c.1799_1800TG>AA	475
		p.V600D	c.1799_1800TG>AT	477

Gene	Exon Codon	Amino Acid Change	Nucleotide Change	Cosmic ID
		p.V600G	c.1799T>G	6137
		p.V600K	c.1798_1799GT>AA	473
		p.V600R	c.1798_1799GT >AG	474
		p.V600M	c.1798G>A	1130

3. TECHNOLOGICAL PRINCIPLES

The IntelliPlex BRAF V600 Mutation Kit utilizes two technologies, SelectAmp and πCode, to achieve high sensitivity multiplex mutation detection.

SelectAmp Technology

SelectAmp technology enables mutation-specific multiplex PCR amplification by blocking amplification of wild-type sequences with Locked Nucleic Acid (LNA). The subsequent selective PCR amplification of mutated sequences increases assay sensitivity and specificity.

πCode MicroDisc

πCode MicroDisc are manufactured to generate up to 85,000 distinct circular image patterns for multiplexing applications. Each πCode MicroDisc has a distinct circular image pattern, which corresponds to a specific capture agent conjugated to the surface of the disc. πCode tagged with different capture agents are pooled, enabling specific detection of multiple analytes in a one-well reaction.

Detection Principle

The test is based on five processes listed as follows:

1. DNA extraction from formalin-fixed paraffin-embedded (FFPE) specimens
2. Mutation-specific multiplex PCR amplification
3. Hybridization of PCR amplicons with mutation-specific probe tagged πCode in a one-well reaction
4. Fluorescent labeling with streptavidin-phycoerythrin
5. Image pattern decoding and fluorescent signal detection by the PlexBio® 100 Fluorescent Analyzer

4. WARNINGS AND PRECAUTIONS

- For in vitro diagnostic use.
- This assay kit should only be used by qualified laboratory personnel.
- Separate, dedicated rooms and equipment for pre- and post- PCR process with unidirectional manner to avoid any contaminations are required.
- Pre-PCR process preparation should be operated in laminar flow hood to avoid contamination.
- Do not use a kit or reagent past its expiration date.
- Note that tumor samples are non-homogeneous in terms of genotype, and may contain non-tumor sections, which can cause false negative results.
- Reagent components have been diluted optimally. Further dilution of the component reagents is not recommended.
- Specimens should be handled as infectious material. Please follow universal precautions for safe use.
- Store assay kits and reagents according to the product label and instructions.
- Do not mix reagents from different lots.
- Dispose of unused reagents, specimens and waste according to applicable central/federal, state, and local regulations.
- Wear powderless gloves and do not touch and make any markings on the bottom of the plate at any time, as fingerprints and markings may interfere with decoding and signal acquisition.
- General laboratory precautions should be taken:

- Do not pipette by mouth.
- Wear protective clothing (e.g., disposable powderless gloves and laboratory coats) and eye protection.
- Do not eat, drink or smoke in the laboratory.
- Wash hands thoroughly after handling samples and reagents.

- The workspace, including racks and pipettes, should be thoroughly cleaned and wiped with 0.5% sodium hypochlorite solution followed by wiping with a 70% ethanol solution. A 1:10 dilution of household bleach will produce a 0.5% sodium hypochlorite solution.
- Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.
- Material Safety Data Sheets (SDS) are available upon request from PlexBio Customer Service.

5. QUALITY CONTROL

The IntelliPlex BRAF V600 Mutation Kit contains a series of internal control πCode MicroDiscs that monitor the PCR amplification, SA-PE incubation procedure and background noise. Those controls must meet the specification in each test well with intensities above the cutoffs from the same run, or the run will be considered failed. The external controls (positive control and negative control) monitor the whole testing procedure to prevent false positive and false negative results. The test is considered invalid if any of the controls fail.

6. KIT COMPONENTS

The IntelliPlex BRAF V600 Mutation Kit contains sufficient reagents for up to 24 tests. Kit components include:

(1) BRAF KIT Reaction Mix
Ref. No.: 20097
Quantity & Volume: 1 vial, 240 µL/vial
Description: For PCR amplification
Contents: MyFi 5X Reaction Buffer, MyFi DNA polymerase (Microbial), buffered solution containing $MgSO_4$ and dNTPs

(2) BRAF KIT Primer Mix
Ref. No.: 20098
Quantity & Volume: 1 vial, 240 µL/vial
Description: For PCR amplification
Contents: ~4 µM Primer (including biotin-labeled primers)

(3) BRAF KIT πCode MicroDisc
Ref. No.: 20099
Quantity & Volume: 1 vial, 480 µL/vial
Description: For PCR amplicon capture
Contents: πCode MicroDisc, Glycerol, Phosphate buffered saline, 0.1% Albumin- from bovine (Biological), <0.1% EDTA and <0.1% Sodium azide

(4) BRAF KIT POS Control
Ref. No.: 20101
Quantity & Volume: 1 vial, 120 µL/vial
Description: Assay positive control
Contents: BRAF plasmid DNA (Microbial), Tris-EDTA Buffer

(5) NEG Control
Ref. No.: 20549
Quantity & Volume: 1 vial, 120 µL/vial
Description: Assay negative control
Contents: Nuclease-free water

(6) SA-PE Solution
Ref. No.: 20007
Quantity & Volume: 1 bottle, 7 mL/bottle
Description: Streptavidin-phycoerythrin for fluorescent signal acquisition
Contents: Phosphate buffered saline, 0.5% Streptavidin-phycoerythrin, 1% Albumin- from bovine (Biological), <0.1% Sodium azide

(7) Hy Buffer
Ref. No.: 20547
Quantity & Volume: 1 bottle, 2.4 mL/bottle
Description: For hybridization
Contents: Saline-Sodium Phosphate-EDTA

NOTE: POS Control, NEG Control and Hy Buffer refer to positive control, negative control and hybridization buffer, respectively.

7. MATERIALS AND EQUIPMENT REQUIRED BUT NOT SUPPLIED

Required products for compatibility with IntelliPlex kits:

- 96-well plate (PlexBio; Cat. No. 80025 or Greiner Bio-one; Cat. No. 655101)
- IntelliPlex® 1000 πCode Processor (PlexBio; Cat. No. 80033)
- PlexBio 100 Fluorescent Analyzer (PlexBio; Cat. No. 80000)
- U Tray (PlexBio; Cat. No. 80023)
- V Tray (PlexBio; Cat. No. 80024)
- DeXipher™ MD (Required: PlexBio; Cat. No. 80051)
- 10X Assay Wash Buffer (PlexBio; Cat. No. 80220)
- Deionized water for dilution of 10X Assay Wash Buffer

Required components:

- Qubit™ Fluorometer with dedicated quantitative reagents (Invitrogen; any models) or equivalent
- FFPE DNA extraction kit (Recommended: QIAamp DNA FFPE Tissue Kit, Qiagen; Cat. No. 56404) or equivalent (Stellar FFPE DNA Extraction Kit, PlexBio; Cat. No. 83025)
- Clean tubes for PCR reaction (Gunster; Cat. No. MB-P08A or equivalent)
- Dedicated micropipette
- Filter tips for micropipette
- Disposable powderless gloves
- Vortex mixer
- Micro-centrifuge
- Thermocycler (Recommended: MiniAmp™ Thermal Cycler, Applied Biosystems™; Cat. No. A37834 or equivalent)
- Industrial Computer (Recommended: PlexBio; Cat. No. 80002)

8. STORAGE, STABILITY AND TRANSPORTATION

Storage
All kit components should be stored at 2-8°C.

Stability

Do not use any kit that has expired. All unopened components are stable up to the expiration date on the label if handled and stored under the recommended conditions.

Transportation
The shipping temperature for the kit is 2-8°C. If the kit package or components are incomplete, please contact PlexBio customer service (service@plexbio.com).

9. INSTRUMENT AND SOFTWARE

Instrument

Please refer to the instrument user manual for complete operation instructions (Thermocycler, IntelliPlex 1000 πCode Processor and PlexBio 100 Fluorescent Analyzer).

Software Installation

The BRAF V600 Mutation Kit has a designated Kit App and ENC file. The Kit App contains the πCode target assignments and the ENC file includes the lot number and expiration date. Please make sure you have the Kit App installed and the ENC file imported into DeXipher before your first assay run.

Kit App Installation

1. Visit www.plexbio.com and download the **BRAF V600 Mutation Kit App**.
2. Click on the "Installer" in the APP folder and follow the instructions to complete Kit App installation.

NOTE:
The Kit App only needs to be installed once. Version updates will be notified by customer service.

ENC File Installation

1. Visit www.plexbio.com and download the **BRAF V600 Mutation Kit** ENC file. Each kit lot number will have a unique ENC file, so you will need to download a new ENC file each time you purchase a kit with a different lot number. Make sure to select the ENC file with the lot number that corresponds to your kit.
2. Save the ENC file to your computer.
3. Follow the PlexBio 100 Fluorescent Analyzer User Manual to import the ENC file.

10. SPECIMENS

Specimen Collection

The **IntelliPlex BRAF V600 Mutation Kit** has been validated to be used for formalin-fixed paraffin embedded tissues (FFPET) from colorectal tumor tissues. It is recommended to extract FFPE DNA with QIAamp DNA FFPE Tissue Kit (Cat. No. 56404) for downstream PCR amplification.

NOTE:

- FFPET specimens may be stored ≤ 30°C for up to 12 months after the date of tissue collection and processing. The optimal tissue fixation time for test should be less than 72 hr.
- Only FFPET sections of 10-µm thickness containing at least 10% tumor content are to be used in the BRAF Mutation Test. Any specimen containing less than 10% tumor content should be macro-dissected prior to deparaffinization.
- Do not use stained FFPE specimens which could generate invalid and/or incorrect results.
- The presence of melanin (PCR inhibitor) may cause a false negative result or an invalid result. When melanin inhibition is suspected, repeat testing on an unpigmented FFPE tissue section.

Specimen Transportation

FFPE specimens can be transported at room temperature.

Storage of Extracted DNA

Extracted DNA can be stored at 2°C to 8°C for immediate use (≤ 24 hours), or at -15°C to -25°C for long-term (> 24 hours) storage. Do not subject the extracted DNA to repeated freeze/thaw cycles.

11. BEFORE YOU START

1. Check that the Kit App has been installed and the lot specific ENC file has been imported to DeXipher.
2. Check that you have 20 µL of extracted DNA (≥ 0.5 ng/µL) ready for analysis.

12. ASSAY PROCEDURE

Warning:
Read the instructions carefully and follow every step of the assay protocol correctly.

12.1 DNA Quantification

1. Quantify the extracted DNA using a Qubit Fluorometer with dedicated quantitative reagents (or equivalent) according to the manufacturer's protocol.
2. The DNA stock concentration should be ≥ 0.5 ng/µL to ensure optimal assay performance. Each PCR reaction uses 20 µL of a 0.5 ng/µL DNA working stock (10 ng DNA input). Please prepare working stock for all samples before preparing PCR. DNA input amounts lower or higher than 10 ng per reaction are not recommended.

12.2 Multiplex PCR Amplification

1. Vortex to mix each sample before use.
2. Spin down and keep samples on ice.
3. Prepare the PCR Reaction:

For each PCR reaction:

BRAF Reaction Mix	10 µL
BRAF Primer Mix	10 µL
Sample/POS Control/NEG Control	20 µL
Total volume	40 µL

NOTE:

- The amount of Reaction Mix and Primer Mix required for a Master Mix depends on the number of reactions. Always prepare a surplus.
- Both POS Control and NEG Control are required for test validity and report generation and must be included in each assay run.

4. Mix by tapping the tubes and spin down before placing the tubes on the thermocycler. Set up the PCR program conditions as below:

PCR Program Conditions*

Temp. (˚C)	Time	Cycles
95	5 min	-
95	20 sec	36
70	20 sec	
60	60 sec	
4	Hold	-

NOTE: *Ramp rate: 3°C/sec (ABI MiniAmp™ Cat. No. A37834).*

12.3 DNA Hybridization and SA-PE Reaction

1. **Prepare 1X Wash Buffer:** Transfer 100mL of the 10X Assay Wash Buffer (PlexBio; Ref: 80220) to the IntelliPlex 1000 πCode Processor 1L Wash Buffer bottle and add 900 ml deionized water. Mix by swirling.

   NOTE: The prepared 1X Wash Buffer can be used for up to one week. Please always check the Wash Buffer is sufficient for assay runs. Additional 10X Assay Wash Buffer can be ordered from PlexBio (Ref. No: 80220).

   IntelliPlex 1000 πCode Processor Wash Buffer consumption:

Procedure	Wash Buffer Consumption (mL)
Self-test	50 mL
DNA & RNA program (1 lane, up to 8 tests)	150 mL
DNA & RNA program (3 lanes, up to 24 tests)	220 mL

2. **Add 20 µL πCode MicroDisc to 96 well plate:** Mix by vortexing the **BRAF πCode** for 10 seconds, then, by pipetting, add 20 µL of the πCode to each well directly. Vortex the tube of πCode every four wells in between dispensing to ensure homogeneous suspension.

   NOTE: Each amplified PCR products (including samples, POS and NEG control) should be added into wells lane wise, in order of A1, B1…H1 and followed by A2, B2…H2 and so on.

3. **Add 100 µL of Hy Buffer** to each well.
4. Spin down the PCR products.
5. **Denature the PCR products** on the thermocycler by heating at 95˚C for 7 minutes, immediately cooled on ice/ cooler or thermocycler to ensure the denatured status. Spin down before use. Use immediately (within 1 hour after denaturation).

   NOTE: Pay attention to the lid temperature of thermocycler while taking out the denatured PCR products.

6. **Add 20 µL of the denatured PCR products** to each well.
7. **Pipet the desired volume of SA-PE solution** into the V Tray in SA-PE tank. Please note that the dead volume of the V Tray is **500 µL** for up to 6 selected lanes or **800 µL** if more than 6 lanes are selected. The minimum usage of SA-PE is **one lane (900 µL)**.

   Calculation Example:
   For a 3-lane reaction, the required SA-PE solution volume is at least:
   400 µL x 3 lanes + 500 µL(dead volume)= 1.7 mL
   It is recommended to add extra solution volume into the V Tray to ensure sufficient dispensing volume.

   NOTE: List of Required SA-PE Solution by Lane(s).

Number of Processed Lane(s)	Required SA-PE Solution (µL)
1	900
2	1300
3	1700
4	2100
5	2500
6	2900
7	3600
8	4000
9	4400
10	4800
11	5200
12	5600

- SA-PE solution should be kept in the dark.
- **Do not** reuse the leftover SA-PE solution and V Tray tank. Replace a new V Tray with every assay run.

8. **Run hybridization and wash:** This assay uses the **DNA/RNA program** in the **Molecular Assay** window of the IntelliPlex 1000 πCode Processor. Refer to the IntelliPlex 1000 πCode Processor operation manual and follow the instructions to run the built-in assay program (Homepage/ Molecular Assay/ Well Selection/ DNA/RNA/ Confirm procedure conditions/ Start Running). The plate will be ready for decoding once the program is finished.

   NOTE:

   - IntelliPlex 1000 πCode Processor must be maintained properly and regularly.
   - **Do not** open the door when the instrument is in operation.
   - The kit contains sufficient reagents for 6 runs of tests (including POS and NEG controls) for a maximum of 24 tests.

12.4 Image Decoding and Fluorescent Detection

1. Follow the PlexBio 100 Fluorescent Analyzer User Manual to set up the read.

   NOTE:

   - PlexBio 100 Fluorescent Analyzer must be calibrated regularly (once per month).
   - Check that the correct ENC file has been imported.
2. Launch DeXipher to run the **Qualitative Assay**.
3. Mark the wells for sample, positive and negative controls.
4. Enter sample information and assay name. Place the plate into the device with the correct orientation as shown on the screen.
5. The raw data will be analyzed through the kit ENC to generate the mutation call report.

   NOTE:

   - A single run can include from 2 to 96 tests (including POS and NEG controls) per 96 well Microwell plate. When running more than 24 specimens, multiple IntelliPlex BRAF V600 Mutation Kits of the same lot will be required.

13. DISCLAIMERS

Negative Test Result

A negative test result means that the targeted mutation was not detected by the kit. Experimental errors or other causes may lead to false negative results. Interpretation of the results should consider these possibilities and be made in combination with other clinical findings.

Positive Test Result

A positive test result means that the targeted mutation was detected by the kit. Experimental errors or other causes may lead to false positive results. Interpretation of the results should consider these possibilities and be made in combination with other clinical findings.

14. INTERPRETATION OF RESULTS

Table 2. Interpretation of Result

Test Result	Reported Result	Interpretation
Mutation Detected	Ex. V600E1 (Refer to Table 1 for details)	Targeted mutation detected
Mutation Not Detected	None	Targeted mutation not detected

Test Result	Reported Result	Interpretation
Invalid Assay	Invalid	**Possible Causes:** 1. PCR Inhibition (presence of inhibitor in the sample) 2. Improper stored reagents 3. Low sample DNA input or quality 4. Low πCode Disc Count (the πCode tube was not vortexed before pipetting) 5. Reagents were not added properly 6. Failed Blank πCode Control 7. Sample quality due to improper fixation process or storage condition

NOTE:

- All runs and specimen validation were performed by the dedicated KIT APP along with IntelliPlex 1000 πCode Processor and PlexBio 100 Fluorescent Analyzer.
- In case of heterogeneity of samples or multiple mutations, only the dominantly detected mutation is reported. "Mutation Detected" indicates that the signal for at least one mutation site is greater than the cutoff value of the corresponding target. When multiple mutations are detected in a sample, only the one that exhibits the highest signal is reported.

15. ANALYTICAL PERFORMANCE

Limit of Blank (LoB)

The limit of blank (LoB) was determined by two operators performing eight replicates of wild-type BRAF cell line (K562) and duplicates of 10 wild-type BRAF FFPE specimens across three days on two reagent lots. Duplicates of another 61 wild-type FFPE specimens from different biobank and procurement year were also tested. Only "No Mutation Detected" results were observed in these wild type samples.

The cutoff values of each targeted mutations were then determined by the measured maximum analytical signal intensity values, respectively.

Limit of Detection (LoD)

The limit of detection (LoD) was determined by two operators each using two reagent lots performing triplicates of each LoD testing across three days per reagent lot. Each mutation was tested at five mutation levels ranging from 0.05 to 2.5% with a plasmid blend serially diluted with wild-type BRAF cell line (K562) DNA. The LoDs of each lot were determined based on a positive hit rate at 95% in PriProbit analysis (Table 3). The LoDs ranged from 0.29~1.57%.

Table 3. Limit of Detection (LoD)

Amino Acid Change	Nucleotide Change	LoD (% Mutation)
p.V600E1	c.1799T>A	1.30
p.V600E2	c.1799_1800TG>AA	0.94
p.V600D	c.1799_1800TG>AT	1.57
p.V600G	c.1799T>G	0.29
p.V600K	c.1798_1799GT>AA	0.42
p.V600R	c.1798_1799GT >AG	0.49
p.V600M	c.1798G>A	1.22

Repeatability

The repeatability was determined by two operators across three reagent lots, two sets of instrument and 10 non-consecutive testing days. Quadruplicate runs were performed per reagent lot per day for a total of 40 runs at one site. Repeatability was demonstrated with four wild-type FFPE samples, low level mutant (1x-3x LoD) and high level mutant (2x-9x LoD). The accuracy of all tested mutation levels was at least 98% (39/40) across all mutations.

Table 4. Repeatability Accuracy

Amino Acid Change	Mutation (%)	Mutation Not Detected / Detected	Accuracy (%)
p.V600E1	2.82	0/40	100
	8.47	0/40	100
p.V600E2	2.14	0/40	100
	6.42	0/40	100
p.V600D	1.85	0/40	100
p.V600G	0.83	0/40	100
	2.50	0/40	100
p.V600K	0.34	1/39	98
	1.01	0/40	100
p.V600R	0.91	0/40	100
	2.73	0/40	100
p.V600M	2.12	0/40	100
	6.35	0/40	100
WT FFPE 1	-	20/0	100
WT FFPE 2	-	20/0	100
WT FFPE 3	-	20/0	100
WT FFPE 4	-	20/0	100

Reproducibility

The reproducibility was determined by two operators per site across three testing sites using one reagent lot, one set of instrument per site and across five non-consecutive days with four wild-type FFPE samples, low level mutant (1x-3x LoD) and high level mutant (2x-9x LoD). Each run included replicate testing of each mutation level and four wild type samples. Accuracy across mutations were at least 95% (57/60) (Table 5). Across all variance components (i.e., site/instrument, operator, and day), the overall coefficient of variation is smaller than 6% across all panel members (Table 6).

Table 5. Reproducibility Accuracy

Amino Acid Change	Mutation (%)	Mutation Not Detected / Detected	Accuracy (%)
p.V600E1	2.82	1/59	98.3
	8.47	0/60	100
p.V600E2	2.14	0/60	100
	6.42	0/60	100

Amino Acid Change	Mutation (%)	Mutation Not Detected / Detected	Accuracy (%)
p.V600D	1.85	0/60	100
p.V600G	0.83	0/60	100
	2.50	0/60	100
p.V600K	0.34	3/57	95
	1.01	0/60	100
p.V600R	0.91	0/60	100
	2.73	0/60	100
p.V600M	2.12	0/60	100
	6.35	0/60	100

Table 6. Reproducibility Coefficient

Mutation	Mutation (%)	Overall Coefficient
V600E1	2.82	2.94%
	8.47	0.00%
V600E2	2.14	0.00%
	6.42	0.00%
V600D	1.85	0.00%
V600G	0.83	0.00%
	2.5	0.00%
V600K	0.34	5.26%
	1.01	0.00%
V600R	0.91	0.00%
	2.73	0.00%
V600M	6.35	0.00%
	2.12	0.00%

Cross-Reactivity

Cross-reactivity was evaluated by testing the BRAF homolog (ARAF and RAF1) plasmids. The tested plasmids were blended with 5% BRAF p.V600E1 in a background of ARAF or RAF1 DNA. Each group was performed in triplicate per day across two days. No cross reactivity was observed.

Cross-Contamination

This test is designed to assess cross-contamination during the assay operation steps, which may lead to false positive results. Wild-type and BRAF p.V600E1 mutation FFPE samples were arranged in alternating order during PCR reaction and sample hybridization to test for carryover of mutation signals to wild type wells. No cross-contamination was observed.

Carryover Interference

This test is designed to evaluate the impact of potential substances carried over from the QIAamp DNA FFPE Tissue Kit. Triplicate testing of BRAF p.V600E1 mutation FFPE samples with each potential interference substance (as listed in Table 7) added before the PCR step showed no interference on kit performance.

Table 7. Interfering Substances Tested

Interfering Substance	Assumed Interference Residual Volume (µl / 20µl DNA)
Xylene	$4*10^{-5}$
Ethanol	$2.7*10^{-4}$
Buffer ATL	$1.08*10^{-4}$
Proteinase K	$2.64*10^{-6}$
Buffer AL	$2.66*10^{-4}$
Wash Buffer AW1	0.1
Wash Buffer AW2	1

Method Comparison

The performance of IntelliPlex BRAF V600 Mutation Kit was compared to Sanger sequencing, which is considered to be the gold standard. A total of 60 FFPE colon cancer specimens were analyzed; the results are summarized in Table 8. Concordance between IntelliPlex BRAF V600 Mutation Kit and Sanger sequencing was 100% positive agreement (sensitivity) and 98.19% negative agreement (specificity). The overall agreement was 98.33%.

Table 8. Comparison of the IntelliPlex BRAF V600 Mutation Kit with the Sanger Sequencing

		Sanger Sequencing	
		Mutation Detected	Mutation Not Detected
IntelliPlex BRAF V600 Mutation Kit	Mutation Detected	5	1
	Mutation Not Detected	0	54
Positive agreement: 100% Negative agreement: 98.18% Overall agreement: 98.33%			

16. TROUBLESHOOTING

The troubleshooting listed below addresses possible problem causes and solutions provided during assay procedures.

Problem	Possible Cause	Recommendations
No Valid Assay Assigned	1. No plate inserted. 2. Plate inserted in wrong orientation. 3. No assay APP installed. 4. No ENC file imported. 5. Two or more lots of reagent used.	1. Confirm plate is inserted and repeat reading. 2. Confirm orientation of plate and repeat reading. 3. Install assay APP and repeat reading. 4. Import ENC file and repeat reading. 5. One reagent lot used at a time.

Problem	Possible Cause	Recommendations
Positive Control Fail / Negative Control Fail	1. No POS Control or NEG Control added. 2. DNase contamination. 3. Assay did not work. 4. Cross contamination between samples. 5. Wrong PC/NC wells chose.	1. Ensure POS Control and NEG Control are added. 2. Ensure all operating procedures are followed correctly. Ensure work environment is free of DNase. 3. Make sure all the assay procedures are followed correctly. 4. Clean all surfaces and equipment. Operate pre-PCR and post-PCR in the dedicated area and separate the equipment for use. 5. Choose the correct PC/NC wells and repeat reading.
πCode MicroDiscs Count Fail	DeXipher is unable to detect sufficient πCode MicroDiscs numbers for mutation determination.	
	1. πCode MicroDiscs are not proper dispersed in the well. 2. Not enough πCode MicroDiscs added to well. 3. Microbes exist in buffers. 4. Instrument error or malfunction.	1. Re-disperse the microplate using IntelliPlex 1000 Processor, and repeat reading. 2. Ensure πCode MicroDiscs are well-mixed with proper amount added. 3. Use freshly prepared wash buffer and deionized water for hybridization to reduce πCode MicroDiscs loss rate. 4. Contact PlexBio Customer Service.
SA-PE Monitor Control Fail	Performance of SA-PE is assessed by the SAPE Monitor Control.	
	1. No SA-PE was added or insufficient SA-PE solution for dispensing. 2. SA-PE solution inactivation. 3. Incorrect tested lanes of microplate selected for SA-PE solution dispensing.	1. Make sure all the assay procedures are followed correctly. Calculate sufficient SA-PE solution volume for dispensing. Repeat test. 2. Ensure correct storage condition and minimize the light exposure. Do not use SA-PE past its expiration date. 3. Repeat assay and make sure lanes selected correctly.
Blank Control Fail	“Background” is determined by measuring MFI of an internal control that should not give a signal.	
	1. Wrong hybridization conditions. 2. Residues of SA-PE solution in wells after hybridization. 3. PlexBio 100 Fluorescent Analyzer is not calibrated. 4. Markings on plates.	1. Check correct hybridization program is selected. 2. Ensure all buffers (Wash buffer and deionized water) on IntelliPlex 1000 Processor are fresh-made and sufficient for washing procedures. 3. Perform calibration on PlexBio 100 Fluorescent Analyzer. 4. Do not make any marking on plate.
Internal Control Fail	Internal Control monitors all steps in the procedure and must be positive.	
	1. PCR inhibition exists. 2. PCR procedures are not performed correctly. 3. DNase contamination 4. Hybridization did not work.	1. Follow instructions of sample extraction carefully. Ensure required temperature ranges and centrifugation needs are complied. Ensure complete removal of ethanol. 2. Make sure all PCR procedures are followed correctly. Do not to use expired materials or mixed lots of reagents. Ensure storage conditions are correct. 3. Ensure all the operating procedures are followed correctly. Ensure work environment is free of DNase. 4. Make sure all the assay procedures are followed correctly. Ensure samples are freshly heat-denatured.

Problem	Possible Cause	Recommendations
Reference Gene Fail	Reference Gene monitors quality of tested sample and must be positive.	
	1. No Sample added or absence of human-derived DNA.	1. Ensure human-derived DNA samples are added. Do not use artificial DNA as samples which may generate invalid results.
	2. Insufficient sample input for assays or poor sample quality.	2. Quantify samples and check the sample input and quality. If still remains failed, ensure the collected samples meet specimen requirements. Retest with new samples if needed.
	3. PCR inhibition exists.	3. Follow sample extraction instructions carefully. Ensure required temperature ranges and centrifugation needs are complied. Ensure complete removal of ethanol.
	4. PCR procedures are not performed correctly.	4. Make sure all PCR procedures are followed correctly. Do not to use expired materials or mixed lots of reagents. Ensure storage conditions are correct.

17. SYMBOLS

Symbol	Explanation	Symbol	Explanation
	In-vitro diagnostic use		Catalog number
	Batch number		Consult instructions for use
	Manufacturer		Use by Date
	European Union Conformity		European Authorized Representative
	Contains sufficient for <n> tests		Date of Manufacture
	Temperature limitation		

18. REFERENCES

1. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 2008; 26:5705–5712.
2. Tol J, Nagtegaal ID, Punt CJ. (2009) BRAF mutation in metastatic colorectal cancer. N. Engl. J. Med. 2009;361:98–99.
3. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS. (2009) CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009;58:90-96.
4. Namba H, Nakashima M, Hayashi T, et al. (2003) Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003;88:4393–7.
5. Rowe LR, Bentz BG, Bentz JS. (2006) Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal 2006;3(1):10.
6. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Neil Davis, Ed Dicks, Rebecca Ewing, Yvonne Floyd, Kristian Gray, Sarah Hall, Rachel Hawes, Jaime Hughes, Vivian Kosmidou, Andrew Menzies, Catherine Mould, Adrian Parker, Claire Stevens, Stephen Watt, Steven Hooper, Rebecca Wilson, Hiran Jayatilake, Gusterson Barry A, Colin Cooper, Janet Shipley, Darren Hargrave, Katherine

Pritchard-Jones, Norman Maitland, Georgia Chenevix-Trench, Riggins Gregory J, Bigner Darell D, Giuseppe Palmieri, Antonio Cossu, Adrienne Flanagan, Andrew Nicholson, Ho Judy WC, Leung Suet Y, Yuen Siu T, Weber Barbara L, Seigler Hilliard F, Darrow Timothy L, Hugh Paterson, Richard Marais, Marshall Christopher J, Richard Wooster, Richard Wooster, Michael R, Stratton P, Andrew Futreal. (2002) Mutations of the BRAF gene in human cancer. Nature 2002, 417:949–954.

7. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton Elizabeth A, Bernice Wong, Garson Tsang, Powell B, West Brian L, Shellooe R, Marimuthu A, Nguyen H, Zhang KYJ, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596–599.
8. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, MD, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, ShyrY, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas. (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366:707–714.
9. Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A, Kluger HM, Narayan D, Halaban R. (2010) Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 2010, 8:67.
10. Hoeflich KP, Gray DC, Eby MT, Tien JY, Wong L, Bower Jet al. (2006). Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 66: 999–1006.
11. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med 2015; 373:726-736August 20, 2015

Notice to User

The use of this product and the associated PlexBio instrumentation is covered by one or more issued (US10302640B2, US10859910B2, EP3307867A1, US10436778B2, US10436776B2, US10019815B2, US9063044B2, US10894975B2) and pending US and foreign patents owned by PlexBio Co., Ltd. The purchase of this product includes nontransferable rights to use this amount of the product to practice the methods described therein. No general patent or other license of any kind other than this specific right of use from purchase is granted. Further information on purchasing licenses for other applications can be obtained from PlexBio Co., Ltd. 6F-1, No. 351, Yangguang St., Neihu District, Taipei City 11491, Taiwan.

Trademarks

PlexBio®, PlexBio®, IntelliPlex®, IntelliPrep™, πCode®, πCode™, DeXipher™, DigiPlex®, are trademarks or registered trademarks of PlexBio Co., Ltd. All other product names and any registered and unregistered trademarks mentioned are used for identification purposes only and remain the exclusive property of their respective owners.

Copyright